A comparative health economic evaluation of venetoclax in combination with obinutuzumab versus Chlorambucil in combination with obinutuzumab as first-line treatment for chronic lymphocytic leukemia in China: a cost-effectiveness analysis

Jiatai Du et al.

Cost Effectiveness and Resource Allocation2026https://doi.org/10.1186/s12962-025-00705-warticle
ABDC C
Weight
0.50

What the paper says

This study demonstrates that, the combination of Ven + Obi as a frontline treatment for CLL is superior to Chl + Obi in terms of cost-effectiveness. Sensitivity analysis indicates that treatment costs will significantly decrease after the patent protection period of these drugs expires.

Open paper page →

Cite this paper

https://doi.org/https://doi.org/10.1186/s12962-025-00705-w

Or copy a formatted citation

@article{jiatai2026,
  title        = {{A comparative health economic evaluation of venetoclax in combination with obinutuzumab versus Chlorambucil in combination with obinutuzumab as first-line treatment for chronic lymphocytic leukemia in China: a cost-effectiveness analysis}},
  author       = {Jiatai Du et al.},
  journal      = {Cost Effectiveness and Resource Allocation},
  year         = {2026},
  doi          = {https://doi.org/https://doi.org/10.1186/s12962-025-00705-w},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

A comparative health economic evaluation of venetoclax in combination with obinutuzumab versus Chlorambucil in combination with obinutuzumab as first-line treatment for chronic lymphocytic leukemia in China: a cost-effectiveness analysis

Flags are reviewed by the Arbiter methodology team within 5 business days.


Evidence weight

0.50

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.50 × 0.4 = 0.20
M · momentum0.50 × 0.15 = 0.07
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.